• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

艾地苯醌治疗急性和慢性Leber遗传性视神经病变患者后视觉功能的变化及其与视网膜内层结构的相关性

Changes in Visual Function and Correlations with Inner Retinal Structure in Acute and Chronic Leber's Hereditary Optic Neuropathy Patients after Treatment with Idebenone.

作者信息

Pemp Berthold, Mitsch Christoph, Kircher Karl, Reitner Andreas

机构信息

Department of Ophthalmology, Medical University of Vienna, 1090 Vienna, Austria.

出版信息

J Clin Med. 2021 Jan 4;10(1):151. doi: 10.3390/jcm10010151.

DOI:10.3390/jcm10010151
PMID:33406801
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7795141/
Abstract

Progressive impairment and degeneration of retinal ganglion cells (RGC) and nerve fibers in Leber's hereditary optic neuropathy (LHON) usually cause permanent visual loss. Idebenone is currently the only approved treatment. However, its therapeutic potential in different stages of LHON has not been definitely clarified. We aimed to investigate the changes in visual function and correlations with retinal structure in acute and in chronic LHON patients after treatment with idebenone. Twenty-three genetically confirmed LHON patients were followed during treatment using logMAR charts, automated perimetry and optical coherence tomography (OCT). Mean visual acuity improved significantly in acute patients treated within 1 year from onset (-0.52 ± 0.46 logMAR from nadir), in early chronic patients who started after 1-5 years (-0.39 ± 0.27 logMAR from baseline), and in late chronic patients with treatment initiation after >5 years (-0.33 ± 0.28 logMAR from baseline, < 0.001 all groups). In acute and in chronic patients, strong correlations between OCT and visual function parameters were present only after treatment. This and the sustained visual recovery after treatment may indicate a reactivated signal transduction in dysfunctional RGC that survive the acute phase. Our results support previous evidence that idebenone has therapeutic potential in promoting visual recovery in LHON.

摘要

在莱伯遗传性视神经病变(LHON)中,视网膜神经节细胞(RGC)和神经纤维的进行性损伤及变性通常会导致永久性视力丧失。艾地苯醌是目前唯一获批的治疗药物。然而,其在LHON不同阶段的治疗潜力尚未明确阐明。我们旨在研究急性和慢性LHON患者接受艾地苯醌治疗后视觉功能的变化及其与视网膜结构的相关性。23例经基因确诊的LHON患者在治疗期间使用对数最小分辨角视力表、自动视野计和光学相干断层扫描(OCT)进行随访。发病1年内接受治疗的急性患者平均视力显著改善(从最低点提高-0.52±0.46对数最小分辨角),发病1至5年后开始治疗的早期慢性患者(从基线提高-0.39±0.27对数最小分辨角),以及发病5年以上开始治疗的晚期慢性患者(从基线提高-0.33±0.28对数最小分辨角,所有组P<0.001)。在急性和慢性患者中,仅在治疗后OCT与视觉功能参数之间存在强相关性。这一点以及治疗后持续的视力恢复可能表明急性期存活下来的功能失调RGC中的信号转导被重新激活。我们的结果支持了先前的证据表明艾地苯醌在促进LHON患者视力恢复方面具有治疗潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab9b/7795141/ee048b52a15c/jcm-10-00151-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab9b/7795141/81ebeefa90f0/jcm-10-00151-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab9b/7795141/ffcab9c0c454/jcm-10-00151-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab9b/7795141/be2e4b07d371/jcm-10-00151-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab9b/7795141/3191fbae98cb/jcm-10-00151-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab9b/7795141/4f8d9d551edd/jcm-10-00151-g005a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab9b/7795141/3a9d75c08ab5/jcm-10-00151-g006a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab9b/7795141/a0013ce33133/jcm-10-00151-g007a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab9b/7795141/ee048b52a15c/jcm-10-00151-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab9b/7795141/81ebeefa90f0/jcm-10-00151-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab9b/7795141/ffcab9c0c454/jcm-10-00151-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab9b/7795141/be2e4b07d371/jcm-10-00151-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab9b/7795141/3191fbae98cb/jcm-10-00151-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab9b/7795141/4f8d9d551edd/jcm-10-00151-g005a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab9b/7795141/3a9d75c08ab5/jcm-10-00151-g006a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab9b/7795141/a0013ce33133/jcm-10-00151-g007a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab9b/7795141/ee048b52a15c/jcm-10-00151-sch001.jpg

相似文献

1
Changes in Visual Function and Correlations with Inner Retinal Structure in Acute and Chronic Leber's Hereditary Optic Neuropathy Patients after Treatment with Idebenone.艾地苯醌治疗急性和慢性Leber遗传性视神经病变患者后视觉功能的变化及其与视网膜内层结构的相关性
J Clin Med. 2021 Jan 4;10(1):151. doi: 10.3390/jcm10010151.
2
Visual function in chronic Leber's hereditary optic neuropathy during idebenone treatment initiated 5 to 50 years after onset.发病后 5 至 50 年开始用艾地苯醌治疗莱伯遗传性视神经病变的慢性期的视觉功能。
Graefes Arch Clin Exp Ophthalmol. 2019 Dec;257(12):2751-2757. doi: 10.1007/s00417-019-04444-6. Epub 2019 Sep 3.
3
Optical Coherence Tomography of the Retinal Ganglion Cell Complex in Leber's Hereditary Optic Neuropathy and Dominant Optic Atrophy.Leber 遗传性视神经病变和显性视神经萎缩的视网膜神经节细胞复合体的光相干断层扫描。
Curr Eye Res. 2019 Jun;44(6):638-644. doi: 10.1080/02713683.2019.1567792. Epub 2019 Feb 4.
4
Characteristics of Japanese patients with Leber's hereditary optic neuropathy and idebenone trial: a prospective, interventional, non-comparative study.日本 Leber 遗传性视神经病变患者的特征和依达拉奉的试验:一项前瞻性、干预性、非对照研究。
Jpn J Ophthalmol. 2021 Jan;65(1):133-142. doi: 10.1007/s10384-020-00789-2. Epub 2020 Nov 13.
5
Idebenone protects against retinal damage and loss of vision in a mouse model of Leber's hereditary optic neuropathy.依地酸二钠钙可保护莱伯遗传性视神经病变模型小鼠的视网膜免受损伤和视力丧失。
PLoS One. 2012;7(9):e45182. doi: 10.1371/journal.pone.0045182. Epub 2012 Sep 18.
6
Altering neuronal circuitry with 4-aminopyridine for visual improvement in Leber's hereditary optic neuropathy (LHON).用 4-氨基吡啶改变神经元回路,改善莱伯遗传性视神经病变(LHON)的视力。
Mitochondrion. 2022 Jan;62:181-186. doi: 10.1016/j.mito.2021.12.003. Epub 2021 Dec 13.
7
Leber's hereditary optic neuropathy - Case report.莱伯遗传性视神经病变——病例报告。
Rom J Ophthalmol. 2018 Jan-Mar;62(1):64-71.
8
Idebenone for Leber's hereditary optic neuropathy.艾地苯醌用于治疗Leber遗传性视神经病变。
Drugs Today (Barc). 2016 Mar;52(3):173-81. doi: 10.1358/dot.2016.52.3.2463564.
9
[Past, present, and future in Leber's hereditary optic neuropathy].[莱伯遗传性视神经病变的过去、现在与未来]
Nippon Ganka Gakkai Zasshi. 2001 Dec;105(12):809-27.
10
Macular thickness changes in a patient with Leber's hereditary optic neuropathy.一名患有Leber遗传性视神经病变患者的黄斑厚度变化
BMC Ophthalmol. 2015 Mar 18;15:27. doi: 10.1186/s12886-015-0015-1.

引用本文的文献

1
Predictors of Final Visual Outcome in Patients With Leber Hereditary Optic Neuropathy Treated With Lenadogene Nolparvovec Gene Therapy.接受利纳多基因诺帕罗韦克基因治疗的Leber遗传性视神经病变患者最终视觉结果的预测因素
Invest Ophthalmol Vis Sci. 2025 Jul 1;66(9):42. doi: 10.1167/iovs.66.9.42.
2
Idebenone vs. rAAV2-ND4 gene therapy in the treatment of Leber's hereditary optic neuropathy: An indirect comparison meta-analysis.艾地苯醌与rAAV2-ND4基因疗法治疗Leber遗传性视神经病变:间接比较的荟萃分析
Indian J Ophthalmol. 2025 May 1;73(5):656-664. doi: 10.4103/IJO.IJO_2898_23. Epub 2025 Apr 24.
3
Ganglion Cell Complex Thickness and Visual Function in Chronic Leber Hereditary Optic Neuropathy.

本文引用的文献

1
Real-World Clinical Experience With Idebenone in the Treatment of Leber Hereditary Optic Neuropathy.依地酸-beta-羟乙酯治疗莱伯遗传性视神经病变的真实世界临床经验。
J Neuroophthalmol. 2020 Dec;40(4):558-565. doi: 10.1097/WNO.0000000000001023.
2
Visual function in chronic Leber's hereditary optic neuropathy during idebenone treatment initiated 5 to 50 years after onset.发病后 5 至 50 年开始用艾地苯醌治疗莱伯遗传性视神经病变的慢性期的视觉功能。
Graefes Arch Clin Exp Ophthalmol. 2019 Dec;257(12):2751-2757. doi: 10.1007/s00417-019-04444-6. Epub 2019 Sep 3.
3
Neuroenhancement and neuroprotection by oral solution citicoline in non-arteritic ischemic optic neuropathy as a model of neurodegeneration: A randomized pilot study.
慢性莱伯遗传性视神经病变的神经节细胞复合体厚度与视觉功能
Invest Ophthalmol Vis Sci. 2024 Oct 1;65(12):4. doi: 10.1167/iovs.65.12.4.
4
Elective splenectomy for hematological diseases: a vanishing indication.择期脾切除术治疗血液系统疾病:一个逐渐消失的适应证。
Surg Endosc. 2024 Nov;38(11):6332-6337. doi: 10.1007/s00464-024-11071-8. Epub 2024 Aug 29.
5
The Optic Nerve at Stake: Update on Environmental Factors Modulating Expression of Leber's Hereditary Optic Neuropathy.视神经面临风险:调节Leber遗传性视神经病变表达的环境因素最新进展
Biomedicines. 2024 Mar 6;12(3):584. doi: 10.3390/biomedicines12030584.
6
Therapeutic benefit of idebenone in patients with Leber hereditary optic neuropathy: The LEROS nonrandomized controlled trial.依地酸二钠钙治疗莱伯遗传性视神经病变患者的疗效:LEROS 非随机对照试验。
Cell Rep Med. 2024 Mar 19;5(3):101437. doi: 10.1016/j.xcrm.2024.101437. Epub 2024 Feb 29.
7
Genetic variants affecting NQO1 protein levels impact the efficacy of idebenone treatment in Leber hereditary optic neuropathy.影响 NQO1 蛋白水平的遗传变异影响 idebenone 治疗莱伯遗传性视神经病变的疗效。
Cell Rep Med. 2024 Feb 20;5(2):101383. doi: 10.1016/j.xcrm.2023.101383. Epub 2024 Jan 24.
8
Idebenone Treatment in Patients with OPA1-Dominant Optic Atrophy: A Prospective Phase 2 Trial.艾地苯醌治疗OPA1显性遗传性视神经萎缩患者:一项前瞻性2期试验。
Neuroophthalmology. 2023 Sep 14;47(5-6):237-247. doi: 10.1080/01658107.2023.2251575. eCollection 2023.
9
Leber's Hereditary Optic Neuropathy (LHON): Clinical Experience and Outcomes after Long-Term Idebenone Treatment.Leber遗传性视神经病变(LHON):长期艾地苯醌治疗后的临床经验与结果
Life (Basel). 2023 Sep 30;13(10):2000. doi: 10.3390/life13102000.
10
Diagnosis, treatment, and research status of rare diseases related to birth defects.出生缺陷相关罕见病的诊断、治疗及研究现状
Intractable Rare Dis Res. 2023 Aug;12(3):148-160. doi: 10.5582/irdr.2023.01052.
口服胞磷胆碱治疗非动脉炎性前部缺血性视神经病变模型的神经增强和神经保护作用:一项随机初步研究。
PLoS One. 2019 Jul 26;14(7):e0220435. doi: 10.1371/journal.pone.0220435. eCollection 2019.
4
Propagation and Selectivity of Axonal Loss in Leber Hereditary Optic Neuropathy.Leber 遗传性视神经病变中轴突损失的传播和选择性。
Sci Rep. 2019 Apr 30;9(1):6720. doi: 10.1038/s41598-019-43180-z.
5
Treatment strategies for Leber hereditary optic neuropathy.Leber 遗传性视神经病变的治疗策略。
Curr Opin Neurol. 2019 Feb;32(1):99-104. doi: 10.1097/WCO.0000000000000646.
6
The idebenone metabolite QS10 restores electron transfer in complex I and coenzyme Q defects.依地醌代谢产物 QS10 可恢复复合物 I 和辅酶 Q 缺陷的电子传递。
Biochim Biophys Acta Bioenerg. 2018 Sep;1859(9):901-908. doi: 10.1016/j.bbabio.2018.04.006. Epub 2018 Apr 22.
7
The coma in glaucoma: Retinal ganglion cell dysfunction and recovery.青光眼性昏迷:视网膜神经节细胞功能障碍与恢复。
Prog Retin Eye Res. 2018 Jul;65:77-92. doi: 10.1016/j.preteyeres.2018.04.001. Epub 2018 Apr 6.
8
Querectin improves myelin repair of optic chiasm in lyolecithin-induced focal demyelination model.曲格列汀改善卵磷脂诱导的局灶性脱髓鞘模型视神经交叉髓鞘修复。
Biomed Pharmacother. 2018 May;101:485-493. doi: 10.1016/j.biopha.2018.02.125. Epub 2018 Mar 22.
9
Visual prognosis better in eyes with less severe reduction of visual acuity one year after onset of Leber hereditary optic neuropathy caused by the 11,778 mutation.由11778突变引起的Leber遗传性视神经病变发病一年后,视力下降程度较轻的眼睛视觉预后较好。
BMC Ophthalmol. 2017 Oct 18;17(1):192. doi: 10.1186/s12886-017-0583-3.
10
International Consensus Statement on the Clinical and Therapeutic Management of Leber Hereditary Optic Neuropathy.关于Leber遗传性视神经病变临床与治疗管理的国际共识声明
J Neuroophthalmol. 2017 Dec;37(4):371-381. doi: 10.1097/WNO.0000000000000570.